United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.51, $0.21 worse than the analyst estimate of $3.72. Revenue for the quarter came in at $415.2 million versus the consensus estimate of $427.62 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.